188 related articles for article (PubMed ID: 36003387)
1. Inhibition of PCSK9 enhances the antitumor effect of PD-1 inhibitor in colorectal cancer by promoting the infiltration of CD8
Wang R; Liu H; He P; An D; Guo X; Zhang X; Feng M
Front Immunol; 2022; 13():947756. PubMed ID: 36003387
[TBL] [Abstract][Full Text] [Related]
2. PCSK9 regulates the efficacy of immune checkpoint therapy in lung cancer.
Gao X; Yi L; Jiang C; Li S; Wang X; Yang B; Li W; Che N; Wang J; Zhang H; Zhang S
Front Immunol; 2023; 14():1142428. PubMed ID: 37025995
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of integrin αvβ6 sparks T-cell antitumor response and enhances immune checkpoint blockade therapy in colorectal cancer.
Busenhart P; Montalban-Arques A; Katkeviciute E; Morsy Y; Van Passen C; Hering L; Atrott K; Lang S; Garzon JFG; Naschberger E; Hartmann A; Rogler G; Stürzl M; Spalinger MR; Scharl M
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35131862
[TBL] [Abstract][Full Text] [Related]
4. Augmented Antitumor Effect of Unripe
Lee EJ; Yang JH; Choi JG; Chung HS
Cells; 2022 Sep; 11(18):. PubMed ID: 36139451
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer.
Liu X; Bao X; Hu M; Chang H; Jiao M; Cheng J; Xie L; Huang Q; Li F; Li CY
Nature; 2020 Dec; 588(7839):693-698. PubMed ID: 33177715
[TBL] [Abstract][Full Text] [Related]
6. Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer.
Liu C; Liu R; Wang B; Lian J; Yao Y; Sun H; Zhang C; Fang L; Guan X; Shi J; Han S; Zhan F; Luo S; Yao Y; Zheng T; Zhang Y
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33462141
[TBL] [Abstract][Full Text] [Related]
7. Chang Wei Qing Decoction enhances the anti-tumor effect of PD-1 inhibitor therapy by regulating the immune microenvironment and gut microbiota in colorectal cancer.
Wang T; Wu L; Wang S; Shi X; Liu H; Deng W
Chin J Nat Med; 2023 May; 21(5):333-345. PubMed ID: 37245872
[TBL] [Abstract][Full Text] [Related]
8. Endostatin induces normalization of blood vessels in colorectal cancer and promotes infiltration of CD8+ T cells to improve anti-PD-L1 immunotherapy.
Chu XD; Bao H; Lin YJ; Chen RX; Zhang YR; Huang T; He JS; Huangfu SC; Pan YL; Ding H
Front Immunol; 2022; 13():965492. PubMed ID: 36389685
[TBL] [Abstract][Full Text] [Related]
9. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner.
Zhang QF; Li J; Jiang K; Wang R; Ge JL; Yang H; Liu SJ; Jia LT; Wang L; Chen BL
Theranostics; 2020; 10(23):10619-10633. PubMed ID: 32929370
[TBL] [Abstract][Full Text] [Related]
10. Potentiating CD8
Yuan J; Cai T; Zheng X; Ren Y; Qi J; Lu X; Chen H; Lin H; Chen Z; Liu M; He S; Chen Q; Feng S; Wu Y; Zhang Z; Ding Y; Yang W
Protein Cell; 2021 Apr; 12(4):240-260. PubMed ID: 33606190
[TBL] [Abstract][Full Text] [Related]
11. Low molecular weight heparin synergistically enhances the efficacy of adoptive and anti-PD-1-based immunotherapy by increasing lymphocyte infiltration in colorectal cancer.
Quan Y; He J; Zou Q; Zhang L; Sun Q; Huang H; Li W; Xie K; Wei F
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37597850
[TBL] [Abstract][Full Text] [Related]
12. Targeting PCSK9 reduces cancer cell stemness and enhances antitumor immunity in head and neck cancer.
Yang QC; Wang S; Liu YT; Song A; Wu ZZ; Wan SC; Li HM; Sun ZJ
iScience; 2023 Jun; 26(6):106916. PubMed ID: 37305703
[TBL] [Abstract][Full Text] [Related]
13. Oncolytic adenovirus H101 ameliorate the efficacy of anti-PD-1 monotherapy in colorectal cancer.
Huang L; Zhao H; Shan M; Chen H; Xu B; He Y; Zhao Y; Liu Z; Chen J; Xu Q
Cancer Med; 2022 Dec; 11(23):4575-4587. PubMed ID: 35762456
[TBL] [Abstract][Full Text] [Related]
14. Gallic acid induces T-helper-1-like T
Deng B; Yang B; Chen J; Wang S; Zhang W; Guo Y; Han Y; Li H; Dang Y; Yuan Y; Dai X; Zang Y; Li Y; Li B
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35817479
[TBL] [Abstract][Full Text] [Related]
15. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
Chung YM; Khan PP; Wang H; Tsai WB; Qiao Y; Yu B; Larrick JW; Hu MC
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887262
[TBL] [Abstract][Full Text] [Related]
16. SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation.
Redin E; Garmendia I; Lozano T; Serrano D; Senent Y; Redrado M; Villalba M; De Andrea CE; Exposito F; Ajona D; Ortiz-Espinosa S; Remirez A; Bertolo C; Sainz C; Garcia-Pedrero J; Pio R; Lasarte J; Agorreta J; Montuenga LM; Calvo A
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33658304
[TBL] [Abstract][Full Text] [Related]
17. Stromal reaction inhibitor and immune-checkpoint inhibitor combination therapy attenuates excluded-type colorectal cancer in a mouse model.
Yorita N; Yuge R; Takigawa H; Ono A; Kuwai T; Kuraoka K; Kitadai Y; Tanaka S; Chayama K
Cancer Lett; 2021 Feb; 498():111-120. PubMed ID: 33129954
[TBL] [Abstract][Full Text] [Related]
18. PD-1 blockade combined with IL-33 enhances the antitumor immune response in a type-1 lymphocyte-mediated manner.
He H; Shi L; Meng D; Zhou H; Ma J; Wu Y; Wu Y; Gu Y; Xie W; Zhang J; Zhu Y
Cancer Treat Res Commun; 2021; 28():100379. PubMed ID: 33951555
[TBL] [Abstract][Full Text] [Related]
19. Low baseline plasma PCSK9 level is associated with good clinical outcomes of immune checkpoint inhibitors in advanced non-small cell lung cancer.
Xie M; Yu X; Chu X; Xie H; Zhou J; Zhao J; Su C
Thorac Cancer; 2022 Feb; 13(3):353-360. PubMed ID: 34962050
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of stearoyl-CoA desaturase 1 (SCD1) enhances the antitumor T cell response through regulating β-catenin signaling in cancer cells and ER stress in T cells and synergizes with anti-PD-1 antibody.
Katoh Y; Yaguchi T; Kubo A; Iwata T; Morii K; Kato D; Ohta S; Satomi R; Yamamoto Y; Oyamada Y; Ouchi K; Takahashi S; Ishioka C; Matoba R; Suematsu M; Kawakami Y
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35793868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
